Grossman E, Chang P C, Hoffman A, Tamrat M, Goldstein D S
Hypertension-Endocrine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
Circ Res. 1991 Oct;69(4):887-97. doi: 10.1161/01.res.69.4.887.
The role of alpha 2-adrenoceptors on vascular sympathetic nerve endings in modulating release of the sympathetic neurotransmitter norepinephrine (NE) in humans was examined by measuring the regional rate of appearance of NE in forearm venous plasma (forearm NE spillover [FSO]) in 32 healthy volunteers during intra-arterial infusion of drugs acting at adrenoceptors or directly on vascular smooth muscle. Simultaneous intra-arterial infusions of tracer amounts of [3H]NE were used to calculate the extraction rate of NE in the forearm. Methoxamine or propranolol with epinephrine (PRO + EPI) was used to stimulate alpha-adrenoceptors, yohimbine was used to inhibit alpha-adrenoceptors, and sodium nitroprusside (NIP) was used to produce increases in forearm blood flow directly. Sympathetic efferent activity was manipulated by systemic intravenous infusions of NIP or trimethaphan. Yohimbine and NIP increased and PRO + EPI and methoxamine decreased NE FSO, without effects on systemic blood pressure, heart rate, or arterial levels of catechols. Changes in FSO were flow dependent; therefore, the slope of the relation between the changes in FSO and forearm blood flow was used to evaluate the effects of each drug on regional sympathoneural activity. During administration of yohimbine, the mean slope of the relation between the change in estimated FSO and the change in forearm blood flow was about four times that of the mean slope during administration of NIP (F = 6.35, p less than 0.05). The slopes of the relations between changes in FSO and forearm blood flow were unaffected by systemic trimethaphan or NIP infusion, indicating that the activity of alpha 2-adrenoceptors was not altered during inhibition or reflexive stimulation of sympathetic outflow. The results suggest that alpha 2-adrenoceptors modulate release of NE from vascular sympathetic nerve endings in humans and that the function of these receptors is unchanged during acute changes in junctional NE concentrations.
通过在32名健康志愿者动脉内输注作用于肾上腺素能受体或直接作用于血管平滑肌的药物时,测量前臂静脉血浆中去甲肾上腺素(NE)的局部出现率(前臂NE溢出率[FSO]),研究了α2 - 肾上腺素能受体在调节人类血管交感神经末梢释放交感神经递质NE中的作用。同时动脉内输注微量[3H]NE用于计算前臂中NE的提取率。使用甲氧明或普萘洛尔加肾上腺素(PRO + EPI)刺激α - 肾上腺素能受体,育亨宾用于抑制α - 肾上腺素能受体,硝普钠(NIP)用于直接增加前臂血流量。通过全身静脉输注NIP或三甲噻芬来控制交感传出活动。育亨宾和NIP增加而PRO + EPI和甲氧明降低NE FSO,对全身血压、心率或儿茶酚胺的动脉水平无影响。FSO的变化与血流有关;因此,FSO变化与前臂血流量之间关系的斜率用于评估每种药物对局部交感神经活动的影响。在给予育亨宾期间,估计的FSO变化与前臂血流量变化之间关系的平均斜率约为给予NIP期间平均斜率的四倍(F = 6.35,p小于0.05)。FSO变化与前臂血流量之间关系的斜率不受全身输注三甲噻芬或NIP的影响,表明在抑制或反射性刺激交感神经流出期间α2 - 肾上腺素能受体的活性未改变。结果表明,α2 - 肾上腺素能受体调节人类血管交感神经末梢释放NE,并且在接头处NE浓度急性变化期间这些受体的功能未改变。